Dr. Lamottke first studied biotechnology (Dipl.-Ing.) at the Technical University of Berlin and then Human medicine at the Charité - Universitätsmedizin Berlin. She obtained her license to practice medicine in 2010 and then took up a residency in the Clinical Department of Pediatric Hematology and Oncology at Hannover Medical School. From 2012 to 2015, Dr. Lamottke underwent specialist training in the "Common Trunk" of the Children's Clinic at Hannover Medical School (rotation program for assistant physicians in further training to become specialists in paediatric and adolescent medicine), after which she continued her training in the Clinical Department for Paediatric Haematology and Oncology and obtained the additional qualification in Paediatric Haematology and Oncology in 2019. In spring 2019, Dr. Lamottke took over medical responsibility for the clinic's own haematology laboratory ("collection laboratory"). In addition to her work in the Clinical Department, Dr. Lamottke has been involved in specialized outpatient palliative care for children and adolescents since 2017 and acquired the additional qualification in palliative medicine in 2018.
Parallel to her studies, Dr. Lamottke worked from 2002 to 2007 at the German Rheumatism Research Center Berlin under Dr. Ria Baumgrass in a working group that dealt with the signal transduction of T cells. This is also where she completed her diploma thesis, which was required as part of her biotechnology studies. Her doctorate, which she completed from 2007 to 2009 under Prof. Dr. Orhan Sezer at the Medical Clinical Department with a focus on haematology and oncology at Charité - Universitätsmedizin Berlin (Charité Campus Mitte), investigated the effect of heat shock protein 90 inhibitors in multiple myeloma. At the end of 2018, Dr. Lamottke began working in Prof. Dr. Britta Maecker-Kolhoff's research group alongside her clinical work as part of the BMBF-funded "Integrated Research and Treatment Center Transplantation (IFB-Tx)". In this context, she is primarily concerned with new cell-based therapeutic approaches against refractory viral diseases after stem cell and organ transplantation.
Dr. Lamottke is a member of the Society for Pediatric Hematology and Oncology (GPOH).